Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▼(-28.06% Downside)
Action:UpgradedDate:12/30/25
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn) and bearish technicals (price below key moving averages with negative MACD). Earnings-call developments (NASDAQ compliance, IP/scientific progress, and improved cash/net loss) provide some offset, while valuation signals are limited due to negative earnings and no dividend.
Positive Factors
Expanding patent portfolio
Acurx’s growing set of granted patents across the U.S. and other jurisdictions creates a durable intellectual-property moat for its PolC and ACX-375C programs. That exclusivity supports long-term protection, licensing or partnership leverage and barriers to generic competition if clinical success follows.
Regulatory alignment & PIP
Agreement with regulators and a favorable EMA pediatric opinion materially reduces regulatory uncertainty for Phase 3 planning. QIDP/Fast-Track designations and aligned requirements across FDA/EMA create a clearer, more durable pathway to MAA/NDA and improve prospects for global development execution.
Minimal leverage on balance sheet
Very low debt lowers financial vulnerability and preserves flexibility to raise equity or strike partnerships, a durable structural advantage for a cash‑burning biotech. Minimal leverage reduces insolvency risk during prolonged development timelines and keeps strategic options open for financing Phase 3.
Negative Factors
Pre-revenue, recurring losses
The company has no commercial revenue and persistent net losses, meaning it must rely on external funding until product approval and commercialization. This structural dependence raises dilution and execution risk and will persist until successful regulatory approvals and market uptake occur.
Negative operating & free cash flow
Sustained negative operating and free cash flow with a modest cash balance imply limited runway absent new financing. This structural cash-burn profile threatens the ability to fund costly Phase 3 trials and can force dilutive financings or suboptimal partnerships, affecting long-term strategy execution.
Reduced R&D spending
Material reductions in R&D outlays may preserve near-term cash but risk slowing trial progression, data generation and regulatory timelines. For a clinical-stage developer, prolonged lower R&D investment increases timeline and technical execution risk and can erode partner interest and competitive momentum.
Acurx Pharmaceuticals (ACXP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.86M
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS Growth61.10%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding2,546,717
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)22.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.34
Enterprise Value/Market Cap-1.21K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.39K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Acurx Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
How the Company Makes MoneyAcurx Pharmaceuticals makes money primarily through the development and commercialization of its proprietary antibiotic compounds. As a clinical-stage company, its revenue model includes potential future sales of its lead product candidate, ibezapolstat, once it successfully completes clinical trials and receives regulatory approval. Additionally, Acurx may secure revenue through partnerships, licensing agreements, and collaborations with other pharmaceutical companies for the development and commercialization of its pipeline products. These partnerships could involve upfront payments, milestone payments, and royalties on sales. The company's earnings are also influenced by research grants and funding from governmental or non-governmental organizations interested in combating antibiotic-resistant infections.
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 13, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments, such as achieving NASDAQ compliance, patent expansion, and successful presentations, alongside ongoing financial challenges and significant reductions in R&D expenses. The company's improved financial position and strategic scientific advancements were notable, though the net loss and reduced R&D spending highlight areas of concern.Q3-2025 Updates
Positive Updates
NASDAQ Compliance Achieved
Acurx Pharmaceuticals effected a 1-for-20 reverse stock split, regaining compliance with NASDAQ listing rules with a minimum bid price of $1 per share and a stockholder equity threshold of $2.5 million.
Patent Expansion
The Australian Patent Office granted a new patent for DNA polymerase 3C inhibitors, adding to existing patents in the U.S., Israel, Japan, and India, strengthening intellectual property for ACX-375C program.
Successful Presentation at ID Week
Acurx was selected to present at ID Week in Atlanta, showcasing ibezapolstat's microbiome-sparing properties and new colonic microbiome data, indicating a low probability of increasing risk for certain infections.
Publication in Nature Communications
Results from a collaboration with Leiden University Medical Center were published, revealing structural biology research on ibezapolstat, marking an important milestone in scientific collaboration.
Financial Position Improvement
The company ended the quarter with $5.9 million in cash, compared to $3.7 million at the end of 2024, and raised additional funds from warrant exercises and equity line of credit.
Negative Updates
Decrease in R&D Expenses
Research and development expenses decreased significantly, from $1.2 million in Q3 2024 to $0.4 million in Q3 2025, primarily due to reductions in manufacturing and consulting costs.
Net Loss Reduction
The company reported a net loss of $2 million for Q3 2025, a decrease from $2.8 million in Q3 2024, indicating ongoing financial challenges despite improvements.
Company Guidance
During the third quarter of 2025, Acurx Pharmaceuticals provided several key updates regarding its financial performance and strategic activities. The company effected a 1-for-20 reverse stock split and regained compliance with NASDAQ's minimum bid price and stockholder equity requirements. Financially, Acurx ended the quarter with $5.9 million in cash, up from $3.7 million at the end of 2024, and raised an additional $1.7 million through an equity line of credit. Research and development expenses decreased to $0.4 million from $1.2 million in the same quarter the previous year, while general and administrative expenses remained flat at $1.6 million. The company reported a net loss of $2 million, or $1.23 per diluted share, compared to a $2.8 million loss, or $3.45 per share, in the prior year. Additionally, Acurx highlighted progress in its ibezapolstat program, including new patent grants, scientific publications, and presentations at industry conferences, while continuing to seek funding opportunities for a phase three clinical trial.Acurx Pharmaceuticals Financial Statement Overview
Summary
Early-stage biotech profile with zero revenue, recurring net losses, and negative operating/free cash flow. Losses and burn have improved versus prior periods, and leverage is minimal (very low debt), but funding durability remains a key risk given continued cash outflows.Income Statement
ACXP remains pre-revenue (zero revenue across annual periods and TTM (Trailing-Twelve-Months)), so operating losses continue to drive results. Losses have narrowed versus prior years (EBIT improved from -$14.6M in 2023 to -$14.1M in 2024 and -$9.2M in TTM), but the business is still far from profitability, with net income still negative in every period shown.14
Very Negative
Balance Sheet
The balance sheet shows no meaningful debt (debt-to-equity effectively 0), which reduces financial risk and gives flexibility—an important positive for a biotech company. However, returns are deeply negative (return on equity is materially below zero across periods, including TTM), reflecting ongoing losses and weak capital efficiency; reported equity and assets also swing sharply versus prior years, which increases uncertainty around underlying stability.58
Neutral
Cash Flow
Cash generation remains negative, with operating and free cash flow both below zero in every period shown. While burn improved in TTM (Operating Cash Flow about -$7.9M vs -$10.4M in 2024), free cash flow growth is still negative in TTM, and cash outflows continue to fund ongoing losses—highlighting continued reliance on external financing until revenues materialize.18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.26M | 0.00 | -14.58M | -12.09M | -12.81M | 0.00 |
| Net Income | -9.17M | -14.10M | -14.58M | -12.09M | -12.75M | -4.60M |
Balance Sheet | ||||||
| Total Assets | 6.11B | 3.86M | 7.71M | 9.38M | 13.25M | 3.22M |
| Cash, Cash Equivalents and Short-Term Investments | 5.91B | 3.71M | 7.47M | 9.11M | 12.96M | 3.18M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.50K |
| Total Liabilities | 2.47B | 3.24M | 3.04M | 2.06M | 843.91K | 522.43K |
| Stockholders Equity | 3.64B | 615.12K | 4.67M | 7.32M | 12.41M | 2.70M |
Cash Flow | ||||||
| Free Cash Flow | -7.85M | -10.38M | -9.80M | -7.54M | -5.01M | -3.35M |
| Operating Cash Flow | -7.85M | -10.38M | -9.80M | -7.54M | -5.01M | -3.35M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 8.00M | 6.62M | 8.16M | 3.70M | 14.80M | 4.04M |
Acurx Pharmaceuticals Technical Analysis
Negative
2.78
Price Trends
2.77
Negative
3.98
Negative
5.48
Negative
Market Momentum
-0.29
Positive
23.10
Positive
4.76
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Negative. The current price of 2.78 is above the 20-day moving average (MA) of 2.20, above the 50-day MA of 2.77, and below the 200-day MA of 5.48, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 23.10 is Positive, neither overbought nor oversold. The STOCH value of 4.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $80.49M | -2.44 | -70.22% | ― | 185.71% | 79.03% | |
48 Neutral | $8.96M | -0.23 | -81.97% | ― | -46.88% | 34.83% | |
45 Neutral | $4.86M | -0.22 | -291.07% | ― | ― | 61.10% | |
44 Neutral | $2.44M | -0.18 | -207.73% | ― | 1.70% | -111.67% | |
39 Underperform | $396.08K | >-0.01 | ― | ― | ― | 99.09% |
* Healthcare Sector Average
ACXP
Acurx Pharmaceuticals
1.66
-15.30
-90.21%
IBIO
Ibio
2.38
-1.06
-30.81%
WINT
Windtree Therapeutics
0.01
-3.76
-99.68%
BRTX
BioRestorative Therapies
0.22
-1.38
-86.38%
LIXT
Lixte Biotechnology Holdings
3.04
1.72
130.30%
BOLT
Bolt Biotherapeutics
5.05
-4.68
-48.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.